ALK and non-small cell lung carcinoma: Lorlatinib demonstrated strong activity also for common resistant mutations such as L1196M and G1269A, but it is yet to be proven if the characteristic of overcoming these mutations reflects in better clinical benefit for NSCLC patients, compared to other ALK-i.